<DrugInformationSummary id="CDR0000495778"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about rituximab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/rituximab">Rituximab</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000042613">rituximab</TerminologyLink><GlossaryLink ref="CDR0000045525">rituximab</GlossaryLink><USBrandNames><USBrandName>Riabni</USBrandName><USBrandName>Rituxan</USBrandName><USBrandName>Ruxience</USBrandName><USBrandName>Truxima</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>rih-TUK-sih-mab</TermPronunciation><MediaLink ref="CDR0000705567" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000705566" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Rituximab</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Rituximab is approved to be used alone or with other drugs to treat:</Para><ItemizedList Style="bullet" id="_6"><ListItem><Strong><GlossaryTermRef href="CDR0000444967" dictionary="Cancer.gov" audience="Patient">B-cell</GlossaryTermRef> <GlossaryTermRef href="CDR0000045145" dictionary="Cancer.gov" audience="Patient">acute leukemia</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000478743" dictionary="Cancer.gov" audience="Patient">advanced</GlossaryTermRef> and <GlossaryTermRef href="CDR0000721294" dictionary="Cancer.gov" audience="Patient">CD20</GlossaryTermRef> <GlossaryTermRef href="CDR0000044710" dictionary="Cancer.gov" audience="Patient">positive</GlossaryTermRef>.  Rituximab is used with <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> in children aged 6 months and older whose cancer has not been treated. This use is approved for the Rituxan brand of rituximab.</ListItem><ListItem><Strong>B-cell <GlossaryTermRef href="CDR0000045148" dictionary="Cancer.gov" audience="Patient">non-Hodgkin lymphoma</GlossaryTermRef></Strong> (NHL) that is CD20 positive. Rituximab is used:<ItemizedList Style="bullet" id="_7"><ListItem>alone in adults with <GlossaryTermRef href="CDR0000428287" dictionary="Cancer.gov" audience="Patient">follicular lymphoma</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045757" dictionary="Cancer.gov" audience="Patient">low-grade lymphoma</GlossaryTermRef> that has <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapsed</GlossaryTermRef> or is <GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> (doesnâ€™t respond to treatment)</ListItem><ListItem> with <GlossaryTermRef href="CDR0000346494" dictionary="Cancer.gov" audience="Patient">first-line</GlossaryTermRef> chemotherapy in adults whose NHL has not been treated</ListItem><ListItem>alone as <GlossaryTermRef href="CDR0000045768" dictionary="Cancer.gov" audience="Patient">maintenance therapy</GlossaryTermRef> in adults who are having a <GlossaryTermRef href="CDR0000045652" dictionary="Cancer.gov" audience="Patient">complete</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045819" dictionary="Cancer.gov" audience="Patient">partial response</GlossaryTermRef> to rituximab  and chemotherapy</ListItem><ListItem>alone in adults with <GlossaryTermRef href="CDR0000045757" dictionary="Cancer.gov" audience="Patient">low-grade</GlossaryTermRef> NHL that has not progressed after first-line therapy with <GlossaryTermRef href="CDR0000045253" dictionary="Cancer.gov" audience="Patient">cyclophosphamide</GlossaryTermRef>, <GlossaryTermRef href="CDR0000615324" dictionary="Cancer.gov" audience="Patient">vincristine sulfate</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045492" dictionary="Cancer.gov" audience="Patient">prednisone</GlossaryTermRef> (<GlossaryTermRef href="CDR0000662466" dictionary="Cancer.gov" audience="Patient">CVP</GlossaryTermRef>)</ListItem><ListItem>with <GlossaryTermRef href="CDR0000044916" dictionary="Cancer.gov" audience="Patient">anthracycline</GlossaryTermRef> <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">combination chemotherapy</GlossaryTermRef> in adults with <GlossaryTermRef href="CDR0000428286" dictionary="Cancer.gov" audience="Patient">diffuse large B-cell </GlossaryTermRef>NHL (DLBCL) that has not been treated</ListItem><ListItem>with chemotherapy in children aged 6 months and older with DLBCL or <GlossaryTermRef href="CDR0000045203" dictionary="Cancer.gov" audience="Patient">Burkitt lymphoma</GlossaryTermRef> that is advanced and has not been treated<Para id="_11"> Use in adults is approved for the Riabni, Rituxan, Ruxience, and Truxima brands of rituximab. Use in children is approved for the Rituxan brand of rituximab.</Para></ListItem></ItemizedList></ListItem></ItemizedList><ItemizedList Style="bullet" id="_10"><ListItem><Strong><GlossaryTermRef href="CDR0000044846" dictionary="Cancer.gov" audience="Patient">Chronic lymphocytic leukemia</GlossaryTermRef></Strong> (CLL) that is CD20 positive. Rituximab is used with <GlossaryTermRef href="CDR0000613209" dictionary="Cancer.gov" audience="Patient">fludarabine phosphate</GlossaryTermRef> and cyclophosphamide in adults.  This use is approved for the Riabni, Rituxan, Ruxience, and Truxima brands of rituximab.</ListItem></ItemizedList><Para id="_3">Rituximab is also being studied in the treatment of other conditions and types of cancer.</Para>                          
 <Para id="_8">Rituximab is also available in a different form, combined with <GlossaryTermRef href="CDR0000791166" dictionary="Cancer.gov" audience="Patient">hyaluronidase</GlossaryTermRef>. For more information, see the Drug Information Summary for <DrugRef href="CDR0000790532" url="/about-cancer/treatment/drugs/rituximabandhyaluronidasehuman">Rituximab and Hyaluronidase Human</DrugRef>.</Para></Section><Section id="_About"><Title>More About Rituximab</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/42613">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.30">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a607038.html">Rituximab</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.31"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.32">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C1702">Find Clinical Trials for Rituximab</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2006-10-05</DateFirstPublished><DateLastModified>2024-06-03</DateLastModified></DrugInformationSummary>
